Request the brochure

* Denotes Required Field

Theme: Exploring the way to Biopharma Industrialization and Commercialization in China

With the new State Drug Administration (SDA) reforms streamlining the approval process of new drugs originating overseas and the launch of biosimilar versions of mAbs by domestic companies, the structure of China’s pharmaceutical consumption will shift toward a greater market share of biological therapeutics, especially more complex molecules. China is likely to approve new gene therapy/cell therapy products in next 1-2 years, since dozens of them are already at the clinical trial stage. 

According to, China is the world-leader in terms of where gene-modified cell therapy clinical trials are conducted. Today, more than 130 companies in China are developing cell and gene therapies ranging from chimeric antigen receptor T cell therapy (CAR-T) / T cell receptor therapy (TCR-T) and adeno-associated virus (AAV) to oncolytic virus. China has already become a hotbed for CGT development, ranking second in the world with more than 1,000 clinical trials either conducted or underway and thousands of related patents granted by the Chinese government between 2017 and 2019. Read more…

Snapshot of BIFT 2020

  • Recent Trends and Development for Antibody Therapeutics in China
  • Novel Antibody Development and Immuno-Oncology
  • Clinical Trial Design, Combination Therapy for Innovative Biologics Trails
  • Innovative Platform for Bispecific Antibody Discovery and Engineering
  • Antibody-Drug Conjugates Development and Production
  • Advancement in Cell Line Development and Clone Selection Technologies
  • Quality Control, Protein Characterization, cGMP and Contract Manufacturing
  • Innovative Bio-manufacturing Technologies (including Continuous Processing, Single-use Systems and QbD/PAT)
  • Biologics Formulation, Aggregation and Stability Studies
  • Next-gen Innovative Cell & Gene Therapeutics Development (CAR-T, TCR-T, TIL, AAV…) 
  • Viral and Cell therapy CMC, GMP Production and Quality Control

Event Features

  • 600+ delegates from over 10 countries and regions 
  • 100+ attending organizations
  • 50+ eminent biopharma, biotech and biomanufacturing speakers
  • 70% on average attendees from primary and end user market (biopharma, biotech, CMO, CRO, research institutes etc.) 
  • 60% above company decision making and director level
  • 1 main conference and 4 focused streams
Produced by
Media Partners